| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
Chelidonic acid does not have a specific drug target but acts through multiple mechanisms. It has been shown to inhibit the activity of various enzymes, including phospholipase A2 and certain kinases. The compound has anti-inflammatory effects by inhibiting the production of pro-inflammatory mediators. It also has antioxidant activity by scavenging free radicals. Chelidonic acid may also modulate calcium signaling pathways in cells.
|
|---|---|
| ln Vitro |
Chelidonic acid suppresses IL-6 mRNA expression at 1–10 μM and dose-dependently lowers IL-6 production at 0.1–10 μM [1]. Chelidonic acid (0.1–10 μM) increases cytoplasmic NF-κB activation and decreases caspase-1 and nuclear NF-κB activation [1]. Chelidonic acid has a Ki of 1.2 μM, making it an inhibitor of glutamate decarboxylase. Chelidonic acid does not react with free pyridoxal-P or encourage the synthesis of apoenzymes [2].
Chelidonic acid demonstrates anti-inflammatory activity by inhibiting the production of pro-inflammatory cytokines and mediators. It has analgesic effects in animal models of pain. The compound exhibits antimicrobial activity against various bacteria and fungi. Chelidonic acid also shows hepatoprotective effects by reducing oxidative stress and liver enzyme levels. The compound has been shown to inhibit the activity of phospholipase A2 and other enzymes. |
| ln Vivo |
Chelidonic acid (0.2, 2 mg/kg, orally) can lessen ovalbumin-induced allergy responses in mice [3].
Chelidonic acid has been studied in various in vivo models. In rodents, administration of chelidonic acid has been shown to reduce inflammation, pain, and liver injury. The compound has also been shown to have antimicrobial effects in animal models of infection. Its effects are dose-dependent and mediated through its anti-inflammatory and antioxidant properties. Further research is needed to fully characterize its in vivo pharmacological profile. |
| Enzyme Assay |
The in vitro assay for chelidonic acid typically involves measuring its enzyme inhibitory activity using standard biochemical assays. The compound is tested against enzymes such as phospholipase A2, kinases, or other targets. The IC50 value is determined from the dose-response curve. Antioxidant activity is assessed using DPPH, ABTS, or FRAP assays. Antimicrobial activity is assessed using standard broth dilution or disk diffusion methods.
|
| Cell Assay |
The in vitro cellular assay for chelidonic acid typically involves culturing cell lines such as macrophages, hepatocytes, or cancer cells and treating them with varying concentrations of the compound. Cellular responses such as inflammatory cytokine secretion, oxidative stress markers, cell viability, and apoptosis are measured. The compound's effects on signaling pathways are assessed using Western blotting or reporter gene assays.
|
| Animal Protocol |
In vivo animal studies for chelidonic acid typically involve the administration of the compound to rodents via oral gavage or intraperitoneal injection. Parameters such as inflammatory markers, pain responses, and liver function tests are assessed. The compound's effects on various disease models (e.g., inflammation, pain, or liver injury) are evaluated. The compound is generally well tolerated at moderate doses.
|
| ADME/Pharmacokinetics |
Chelidonic acid is a small molecule with a molecular weight of 184.10 g/mol and a molecular formula of C7H4O6. It is soluble in water and organic solvents. The compound is metabolized in the liver and excreted in urine. It has a short half-life and is rapidly cleared from the body. The compound is stable under normal storage conditions and should be stored in a cool, dry place.
|
| Toxicity/Toxicokinetics |
Chelidonic acid is a naturally occurring compound and is generally well tolerated at moderate doses. However, high doses may cause gastrointestinal irritation or other adverse effects. The compound is intended for research use only and should be handled with appropriate laboratory safety precautions. Standard safety assessments would be required before any clinical application.
|
| References |
|
| Additional Infomation |
Chelidonic acid is a carbonyl compound belonging to the pyran group. It has been reported that Chelidonic acid is found in corn, chelidinium, and other organisms with relevant data. See also: Chelidinium inflorescence (partial).
Chelidonic acid is a naturally occurring organic acid found in Chelidonium majus (greater celandine) and other plants. It is a γ-pyrone derivative that is structurally related to meconic acid. The compound has been studied for its anti-inflammatory, analgesic, antimicrobial, and hepatoprotective effects. It is primarily used in research as a natural product and biochemical tool. The compound has not yet entered clinical trials and is strictly for preclinical research purposes. |
| Molecular Formula |
C7H4O6
|
|---|---|
| Molecular Weight |
184.1031
|
| Exact Mass |
184.001
|
| CAS # |
99-32-1
|
| PubChem CID |
7431
|
| Appearance |
Gray to brown solid powder
|
| Density |
1.821 g/cm3
|
| Boiling Point |
471.3ºC at 760 mmHg
|
| Melting Point |
265 °C (dec.)(lit.)
|
| Flash Point |
204.1ºC
|
| LogP |
0.036
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
13
|
| Complexity |
316
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
PBAYDYUZOSNJGU-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C7H4O6/c8-3-1-4(6(9)10)13-5(2-3)7(11)12/h1-2H,(H,9,10)(H,11,12)
|
| Chemical Name |
4-oxopyran-2,6-dicarboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~10 mg/mL (~54.32 mM)
H2O : ~2.5 mg/mL (~13.58 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (13.58 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (13.58 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: 2 mg/mL (10.86 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication (<60°C). |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.4318 mL | 27.1592 mL | 54.3183 mL | |
| 5 mM | 1.0864 mL | 5.4318 mL | 10.8637 mL | |
| 10 mM | 0.5432 mL | 2.7159 mL | 5.4318 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
